Eddie Joe Sullivan

CIK: 0001889712

Transaction Breakdown

Open Market Buys (P)0 (0.0%)

High conviction signal

Open Market Sales (S)0 (0.0%)

Position reduction

Option Exercises (M)0 (0.0%)

Derivative conversions

Awards (A)2 (100.0%)

Compensation grants

Other (G, F, J, C, D, …)0 (0.0%)

Gifts, tax withholding, conversions, dispositions to the issuer and other codes

Companies & Roles (1)

SABS

SAB Biotherapeutics, Inc.

DirectorOfficer

Discretionary Trading P&L

Holdings

Transaction History (2 total)

SABS
SAB Biotherapeutics, Inc.
Feb 3, 2026
Award(A)
Stock option (right to buy)
Direct
3M shares-
SABS
SAB Biotherapeutics, Inc.
Aug 26, 2025
Award(A)
Stock Option (right to buy)
Direct
3M shares-

		Type	Shares	Price		Ownership
Feb 3, 2026	SABS SAB Biotherapeutics, Inc.	Award(A) Stock option (right to buy)	3,000,000	-	-	Direct
Aug 26, 2025	SABS SAB Biotherapeutics, Inc.	Award(A) Stock Option (right to buy)	3,000,000	-	-	Direct

1-2 of 2 transactions

About Sullivan Eddie Joe

Sullivan Eddie Joe (SEC CIK 0001889712) files insider reports with the SEC as PRESIDENT of SAB Biotherapeutics, Inc. (SABS).

Signal8 holds 2 ownership filings by Sullivan Eddie Joe, all Form 4s, filed between Aug 28, 2025 and Feb 5, 2026. Those filings report 2 transactions, from Aug 26, 2025 to Feb 3, 2026. Signal8's Form 4 history starts in Sep 2024.

The business address on Sullivan Eddie Joe's filings is in MIAMI BEACH, FL.

Recent filings by Sullivan Eddie Joe

Feb 3, 2026: Grant or award of SABS derivative securities (Form 4, code A).
Aug 26, 2025: Grant or award of SABS derivative securities (Form 4, code A).

Other insiders filing for SAB Biotherapeutics, Inc. (SABS)

Kropotova Alexandra, CHIEF MEDICAL OFFICER
Reich Samuel J, CEO
Bausch Christoph Lawrence, CHIEF OPERATING OFFICER
To Lucy
Jain Rita, Director
ZACCARDELLI DAVID, Director

How to read Form 4 transaction codes